Biology and therapy of fibromyalgia. New therapies in fibromyalgia

Lesley M Arnold, Lesley M Arnold

Abstract

Fibromyalgia is a chronic, musculoskeletal pain condition that predominately affects women. Although fibromyalgia is common and associated with substantial morbidity and disability, there are no US Food and Drug Administration-approved treatments. However, progress has been made in identifying pharmacological and non-pharmacological treatments for fibromyalgia. Recent pharmacological treatment studies have focused on selective serotonin and norepinephrine reuptake inhibitors, which enhance serotonin and norepinephrine neurotransmission in the descending pain pathways and lack many of the adverse side effects associated with tricyclic medications. Promising results have also been reported for medications that bind to the alpha2delta subunit of voltage-gated calcium channels, resulting in decreased calcium influx at nerve terminals and subsequent reduction in the release of several neurotransmitters thought to play a role in pain processing. There is also evidence to support exercise, cognitive behavioral therapy, education, and social support in the management of fibromyalgia. It is likely that many patients would benefit from combinations of pharmacological and non-pharmacological treatments, but more study is needed.

References

    1. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum. 1997;40:1928–1939.
    1. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13:189–196. doi: 10.1097/00002508-199709000-00003.
    1. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999;74:385–398.
    1. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002;4:299–305.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172.
    1. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999;74:385–398.
    1. Baranauskas G, Nistri A. Sensitization of pain pathways in the spinal cord: cellular mechanisms. Prog Neurobiol. 1998;54:349–365. doi: 10.1016/S0301-0082(97)00067-1.
    1. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309–338. doi: 10.1146/annurev.ne.07.030184.001521.
    1. Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res. 1993;616:200–210. doi: 10.1016/0006-8993(93)90210-E.
    1. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474. doi: 10.1016/S0301-0082(02)00009-6.
    1. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550–556.
    1. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol. 1992;19:104–109.
    1. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol. 1992;19:90–94.
    1. Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci. 1997;20:404–19. doi: 10.1017/S0140525X97251484.
    1. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, Gomeni C. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford) 2001;40:290–296. doi: 10.1093/rheumatology/40.3.290.
    1. Arnold LM, Keck PE, Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41:104–113. doi: 10.1176/appi.psy.41.2.104.
    1. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis: A double-blind, placebo-controlled study. Arthritis Rheum. 1986;29:655–659.
    1. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32–40.
    1. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum. 1995;38:1211–1217.
    1. Goldenberg DL, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852–1859.
    1. Caruso I, Puttini PCS, Boccassini L, Santandrea S, Locati M, Volpato R, Montrone F, Benvenuti C, Beretta A. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1987;15:154–159.
    1. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. Arthritis Rheum. 1988;31:1535–1542.
    1. Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol. 1989;16(Suppl 19):140–143.
    1. Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991;18:452–454.
    1. Kobayashi H, Hasegawa Y, One H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996;311:29–35. doi: 10.1016/0014-2999(96)00402-5.
    1. Bibolotti E, Borghi C, Pasculli E, Regoli F, Tavoni A, Baroni L, Castrogiovanni P, Pasero G. The management of fibrositis: A double-blind comparison of maprotiline (Ludiomil), chlorimipramine, and placebo. J Clin Trials. 1986;23:269–280.
    1. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51:9–13. doi: 10.1002/art.20076.
    1. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants. A meta-analysis. J Gen Intern Med. 2000;15:659–666. doi: 10.1046/j.1525-1497.2000.06279.x.
    1. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Rokponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279–1286. doi: 10.1093/rheumatology/37.12.1279.
    1. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol. 1989;16(Suppl 19):98–103.
    1. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain. 1996;4:37–47. doi: 10.1300/J094v04n03_05.
    1. Kempenears CH, Simenon G, Vander Elst M, Fransolet L, Mingard P, de Maertelaer V. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology. 1994;30:66–72.
    1. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23:255–259.
    1. Nørregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445–449. doi: 10.1016/0304-3959(94)00218-4.
    1. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. Am J Med. 1987;83(Suppl 5A):107–110. doi: 10.1016/0002-9343(87)90862-X.
    1. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 1991;20:294–302.
    1. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia – a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:27–35. doi: 10.1053/eujp.1999.0148.
    1. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Won DT, Perry KW. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology. 2002;160:353–361. doi: 10.1007/s00213-001-0986-x.
    1. Nemeroff CB, Owens MJ. Neuropharmacology of paroxetine. Psychopharmacol Bull. 2003;37(Suppl 1):8–18.
    1. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE., Jr A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191–197. doi: 10.1016/S0002-9343(01)01089-0.
    1. Patkar AA, Peindl K, Krulewicz S, Mannelli P, Lindsay A, Masand PS. History of depressive and anxiety disorders as predictors of response in fibromyalgia. Presented at the 158th Annual Meeting of the American Psychiatric Association. 2005. NR 382.
    1. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388–2395. doi: 10.1001/jama.292.19.2388.
    1. Beliles K, Stoudemire A. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics. 1998;39:S2–S19.
    1. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE., Jr An open clinical trial of venlafaxine in fibromyalgia. Psychosomatics. 1998;39:14–17.
    1. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;37:1561–1565. doi: 10.1345/aph.1D112.
    1. Zijlstra TR, Barendregt PJ, van de Laar MAF. Venlafaxine in fibromyalgia: Results of a randomized, placebo-controlled, double-blind trial. Presented at the 66th Annual Meeting of the American College of Rheumatology. 2002. abstract 179.
    1. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Comparative affinity of duloxetine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25:871–880. doi: 10.1016/S0893-133X(01)00298-6.
    1. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry. 2002;63:225–231.
    1. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine 60 mg once daily for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308–315.
    1. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383–390. doi: 10.1016/S0022-3956(02)00060-2.
    1. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45:17–28. doi: 10.1176/appi.psy.45.1.17.
    1. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356. doi: 10.1111/j.1526-4637.2005.00061.x.
    1. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118. doi: 10.1016/j.pain.2005.03.029.
    1. Physicians' Desk Reference. Montvale, New Jersey: Thomson PDR; 2006.
    1. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984. doi: 10.1002/art.20485.
    1. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: Development and validation. J Rheumatol. 1991;18:728–734.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med. 1994;23:129–138.
    1. Fischer AA. Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil. 1986;67:836–838.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised US Department of Health, Education, and Welfare publication (ADM) Rockville, MD: National Institute of Mental Health; 1976. pp. 76–338.
    1. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy. 1992;22:307–319. doi: 10.1016/0168-8510(92)90004-U.
    1. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95.
    1. Ware JE, Sherbourne CD. The SF-36 health status survey: I. Conceptual framework and item selection. Medical Care. 1992;30:473–483.
    1. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15. doi: 10.1016/j.pain.2005.06.031.
    1. Kranzler JD, Gendreau JF, Rao SG. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull. 2002;36:165–213.
    1. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975–1985.
    1. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain. 1975;1:277–299. doi: 10.1016/0304-3959(75)90044-5.
    1. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, Jr, LaMoreaux LK, Martin SA, Sharma U, the Pregabalin 1008-105 Study Group Pregabalin for the treatment of fibromyalgia syndrome. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273. doi: 10.1002/art.20983.
    1. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197. doi: 10.1016/0304-3959(87)91074-8.
    1. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JEJ, editor. Measuring Functioning and Well-being. Durham, NC: Duke University Press; 1992. pp. 232–259.
    1. Belza B, Henke C, Epstein W, Gilliss C. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res. 1993;42:93–99.
    1. Zigmond A, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
    1. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28:187–193.
    1. Drewes AM, Andreasen A, Jennum P, Nielsen KD. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol. 1991;20:288–293.
    1. Grönblad M, Nykänen J, Konttinen Y, Jarvinen E, Helve T. Effect of zopiclone of sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol. 1993;12:186–191. doi: 10.1007/BF02231524.
    1. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double-blind, placebo controlled, modified crossover study. J Rheumatol. 1996;23:529–533.
    1. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. Arthritis Rheum. 1991;34:552–560.
    1. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, Fernandez-Rodriguez A, Hernanz-Mediano W, Gutierrez-Rubio A, de la Iglesia-Salgado JL, Garcia-Lopez A. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain. 1996;65:221–225. doi: 10.1016/0304-3959(95)00199-9.
    1. Scharf MB, Baumann M, Berkokwitz D. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003;30:1070–1074.
    1. Russell IJ, Bennett RM, Michalek JE, Oxybate for FMS Study Group Sodium oxybate relieves pain and improves sleep in fibromyalgia syndrome [FMS]: A randomized, double-blind, placebo-controlled, multi-center clinical trial. Presented at the 69th Annual Meeting of the American College of Rheumatology. 2005. abstract 80.
    1. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63:1–22. doi: 10.1016/S0376-8716(00)00191-5.
    1. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66(Suppl 9):31–41.
    1. Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF. The Xyrem® Risk Management Program. Drug Safety. 2004;27:293–306. doi: 10.2165/00002018-200427050-00002.
    1. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002;43:1493–1497. doi: 10.1046/j.1528-1157.2002.21002.x.
    1. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40:1560–1570.
    1. Sorensen J, Bengtsson A, Backman E, Henricksson KG, Ekselius L, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol. 1995;24:360–365.
    1. Kemple KL, Smith G, Wong-Ngan J. Opioid therapy in fibromyalgia- A four year prospective evaluation of therapy selection, efficacy, and predictors of outcome. Arthritis Rheum. 2003;48:S88.
    1. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: A preliminary prospective study. J Pain. 2006;7:43–48. doi: 10.1016/j.jpain.2005.08.001.
    1. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP, Jr, Vanderah TW, Hunt SP, Hruby VJ, Lai J, Porreca F. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005;116:276–288. doi: 10.1016/j.pain.2005.04.014.
    1. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18:13–19.
    1. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6:250–257. doi: 10.1097/00124743-200010000-00003.
    1. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537–545. doi: 10.1016/S0002-9343(03)00116-5.
    1. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519–527. doi: 10.1002/art.21319.
    1. Senay EC, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH, Woody GE, Cicero TJ. Physical dependence on Ultram® (tramadol hydrochloride): Both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend. 2003;69:233–241. doi: 10.1016/S0376-8716(02)00321-6.
    1. Farber L, Stratz T, Bruckle W, Spath M, Pongratz D, Lautenschlager J, Kotter I, Zoller B, Peter HH, Neeck G, Alten R, Muller W. Efficacy and tolerability of tropisetron in primary fibromyalgia-a highly selective and competitive 5-HT3 receptor antagonist. Scand J Rheumatol Suppl. 2000;113:49–54.
    1. Spath M, Stratz T, Neeck G, Kotter I, Hammel B, Amberger CC, Haus U, Farber L, Pongratz D, Muller W. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol. 2004;33:267–270. doi: 10.1080/03009740410005818.
    1. Rao SG. The neuropharmacology of centrally-acting analgesic medications in fibromyalgia. Rheum Dis Clin North Am. 2002;28:235–259. doi: 10.1016/S0889-857X(01)00004-7.
    1. Henriksson KG, Sörensen J. The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am. 2002;28:343–351. doi: 10.1016/S0889-857X(01)00013-8.
    1. Clark SR, Bennett RM. Supplemental dextromethorphan in the treatment of fibromyalgia. A double blind, placebo controlled study of efficacy and side effects. Arthritis Rheum. 2000;43:S333.
    1. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-Methyl-D-Aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain. 2005;6:323–332. doi: 10.1016/j.jpain.2005.01.357.
    1. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52:2495–2505. doi: 10.1002/art.21191.
    1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28.
    1. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21:180–191.
    1. Hadhazy VA, Ezzo J, Creamer P, Berman BM. Mind-body therapies for the treatment of fibromyalgia. A systematic review. J Rheumatol. 2000;27:2911–2918.
    1. Burckhardt CS, Mannerkorpi K, Hedenberg L, Bjelle A. A randomized, controlled clinical trial of education and physical training for women with fibromyalgia. J Rheumatol. 1994;21:714–720.
    1. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, Rutten-van Molken MP, Pelt RA, van Eek H, Heuts PH. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. J Rheumatol. 1996;23:1237–1245.
    1. Martin L, Nutting A, MacIntosh BR, Edworthy SM, Butterwick D, Cook J. An exercise program in the treatment of fibromyalgia. J Rheumatol. 1996;23:1050–1053.
    1. Wigers SH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. Scand J Rheumatol. 1996;25:77–86.
    1. Nicassio PM, Radojevic V, Weisman MH, Schuman C, Kim J, Schoenfeld-Smith K, Krall T. A comparison of behavioral and educational interventions for fibromyalgia. J Rheumatol. 1997;24:2000–2007.
    1. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain. 2002;18:324–336. doi: 10.1097/00002508-200209000-00008.
    1. Karjalainen KA, Hurri H, Jauhiainen M, Koes BW, Malmivaara A, Roine R, van Tulder M. Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain in working age adults. Cochrane Database Syst Rev. 1999. Art. No.: CD001984. DOI: 10.1002/14651858.CD001984.
    1. Busch A, Schachter CL, Peloso PM, Bombardier C. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev. 2002;(2) Art. No.: CD003786. DOI: 10.1002/14651858.CD003786.
    1. McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum. 1988;31:1135–1141.
    1. Mengshoel AM, Komnaes HB, Forre O. The effects of 20 weeks of physical fitness training in female patients with fibromyalgia. Clin Exp Rheumatol. 1992;10:345–349.
    1. Buckelew CS, Conway R, Parker J, Deuser WE, Read J, Witty TE, Hewett JE, Minor M, Johnson JC, Van Male L, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res. 1998;11:196–209.
    1. Hakkinen A, Hakkinen K, Hannonen P, Alen M. Strength training induced adaptations in neuromuscular function of premenopausal women with fibromyalgia: comparison with healthy women. Ann Rheum Dis. 2001;60:21–26. doi: 10.1136/ard.60.1.21.
    1. Gowans SE, deHueck A, Voss S, Richardson M. A randomized, controlled trial of exercise and education for individuals with fibromyalgia. Arthritis Care Res. 1999;12:120–128. doi: 10.1002/1529-0131(199904)12:2<120::AID-ART7>;2-4.
    1. van Santen M, Bolwijn P, Verstappen F, Bakker C, Hidding A, Houben H, van der Heijde D, Landewe R, van der Linden S. A randomized clinical trial comparing fitness and biofeedback training versus basic treatment in patients with fibromyalgia. J Rheumatol. 2002;29:575–581.
    1. van Santen M, Bolwijn P, Landewe R, Verstappen F, Bakker C, Hidding A, van der Heijde D, Houben H, van der Linden S. High or low intensity aerobic fitness training in fibromyalgia: Does it matter? J Rheumatol. 2002;29:582–587.
    1. Richards SCM, Scott DL. Prescribed exercise in people with fibromyalgia: parallel group randomized controlled trial. BMJ. 2002;325:185–188. doi: 10.1136/bmj.325.7357.185.
    1. Schachter CL, Busch AJ, Peloso PM, Sheppard MS. Effects of short versus long bouts of aerobic exercise in sedentary women with fibromyalgia: A randomized controlled trial. Phys Ther. 2003;83:340–358.
    1. Da Costa D, Abrahamowicz M, Lowensteyn I, Bernatsky S, Drista M, Fitzcharles MA, Dobkin PL. A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia. Rheumatology. 2005;44:1422–1427. doi: 10.1093/rheumatology/kei032.
    1. Valim V, Oliveira L, Suda A, Silva L, de Assis M, Neto TB, Feldman D, Natour J. Aerobic fitness effects in fibromyalgia. J Rheumatol. 2003;30:1060–1069.
    1. Mannerkorpi K, Nyberg B, Ahlmen M, Ekdahl C. Pool exercises combined with an education program for patients with fibromyalgia syndrome. A prospective, randomized study. J Rheumatol. 2000;27:2473–2481.
    1. Mannerkorpi K, Ahlmen M, Ekdahl C. Six- and 24-month follow-up of pool exercise therapy and education for patients with fibromyalgia. Scand J Rheumatol. 2002;31:306–310. doi: 10.1080/030097402760375223.
    1. Cedraschi C, Desmeules J, Rapiti E, Baumgartner E, Cohen P, Finckh A, Allaz AF, Vischer TL. Fibromyalgia: A randomized, controlled trial of a treatment programme based on self management. Ann Rheum Dis. 2004;63:290–296. doi: 10.1136/ard.2002.004945.
    1. King SJ, Wessel J, Bhambhani Y, Sholter D, Maksymowych W. The effects of exercise and education, individually or combined, in women with fibromyalgia. J Rheumatol. 2002;29:2620–2627.
    1. Jones KD, Burckhardt CS, Clark SR, Bennett RM, Potempa KM. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol. 2002;29:1041–1048.
    1. Kingsley JD, Panton LB, Toole T, Sirithienthad P, Mathis R, McMillan V. The effects of a 12-week strength-training program on strength and functionality in women with fibromyalgia. Arch Phys Med Rehabil. 2005;86:1713–1721. doi: 10.1016/j.apmr.2005.04.014.
    1. Dobkin PL, Abrahamowicz M, Fitzcharles MA, Dritsa M, Da Costa D. Maintenance of exercise in women with fibromyalgia. Arthritis Rheum. 2005;53:724–731. doi: 10.1002/art.21470.
    1. Oliver K, Cronan T. Predictors of exercise behaviors among fibromyalgia patients. Prev Med. 2002;35:383–389. doi: 10.1006/pmed.2002.1084.
    1. Williams DA, Cary MA, Groner KH, Chaplin W, Glazer LJ, Rodriguez AM, Clauw DJ. Improving physical functional status in patients with fibromyalgia: A brief cognitive behavioral intervention. J Rheumatol. 2002;29:1280–1286.
    1. Kashikar-Zuck S, Swain NF, Jones BA, Graham TB. Efficacy of cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol. 2005;32:1594–1602.
    1. Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients. A randomized clinical trial. Arch Intern Med. 2005;165:2527–2535. doi: 10.1001/archinte.165.21.2527.
    1. Astin JA, Berman BM, Bausell B, Lee WL, Hochberg M, Forys KL. The efficacy of mindfulness meditation plus Qigong movement therapy in the treatment of fibromyalgia: A randomized controlled trial. J Rheumatol. 2003;30:2257–2262.
    1. Oliver K, Cronan TA, Walen HR, Tomita M. Effects of social support and education on health care costs for patients with fibromyalgia. J Rheumatol. 2001;28:2711–2719.
    1. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17:667–683. doi: 10.1016/S1521-6942(03)00037-8.
    1. Harris RE, Tian X, Williams DA, Tian TX, Cupps TR, Petzke F, Groner KH, Biswas P, Gracely RH, Clauw DJ. Treatment of fibromyalgia with formula acupuncture: Investigation of needle placement, needle stimulation, and treatment frequency. J Altern Complement Med. 2005;11:663–671. doi: 10.1089/acm.2005.11.663.
    1. Assefi NP, Sherman KJ, Jacobsen C, Goldberg J, Smith WR, Buchwald D. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. Ann Intern Med. 2005;143:10–19.
    1. Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17:649–665. doi: 10.1016/S1521-6942(03)00034-2.
    1. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388–2395. doi: 10.1001/jama.292.19.2388.
    1. Arnold LM, Hudson JI, Keck PE, Jr, Auchenbach MB, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry.
    1. Arnold LM. Systemic therapies for chronic pain. In: Wallace DJ, Clauw DJ, editor. Fibromyalgia and Other Central Pain Syndromes. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. pp. 365–388.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa